Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Cobenfy’s launch is tracking against expectations, having surpassed 30,000 total scripts following an FDA approval in late September, according to Lenkowsky.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today annou ...

Scientists have discovered novel drug candidates that could ultimately lead to new effective treatments for conditions caused ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy.

Medically reviewed by Michael MacIntyre, MD Schizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as ...